Legal Representation
Attorney
David Davis
USPTO Deadlines
Next Deadline
In Grace Period
Section 8 (6-Year) Declaration Due (Based on registration date 2019-03-12)
Due Date
March 12, 2025
Grace Period Ends
September 12, 2025
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
21 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Mar 12, 2024 | REM1 | E | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | Loading... |
| Mar 12, 2019 | R.PR | A | REGISTERED-PRINCIPAL REGISTER | Loading... |
| Mar 6, 2019 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Dec 25, 2018 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Dec 25, 2018 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Dec 5, 2018 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Nov 14, 2018 | CNEA | R | EXAMINERS AMENDMENT -WRITTEN | Loading... |
| Nov 14, 2018 | GNEA | O | EXAMINERS AMENDMENT E-MAILED | Loading... |
| Nov 14, 2018 | GNEN | O | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | Loading... |
| Nov 14, 2018 | XAEC | I | EXAMINER'S AMENDMENT ENTERED | Loading... |
| Nov 14, 2018 | CNSA | O | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Nov 13, 2018 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Nov 13, 2018 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Nov 5, 2018 | ALIE | A | ASSIGNED TO LIE | Loading... |
| Oct 24, 2018 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| May 14, 2018 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| May 14, 2018 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| May 14, 2018 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| May 14, 2018 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Feb 10, 2018 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Feb 3, 2018 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
Dietary supplements; pharmaceutical preparations for treating diseases in the nature of cardiovascular diseases, metabolic diseases, allergies and allergy diseases, arthritis, dermatological diseases, inflammatory diseases, eye diseases, pulmonary diseases, cancer, central nervous system disorders, amyotrophic lateral sclerosis, infectious diseases, gastrointestinal diseases and urologic diseases
First Use Anywhere:
0
First Use in Commerce:
0
Classification
International Classes
005